A new chapter for Retrophin began the day the company replaced
Under its current leadership, Retrophin continues to move forward. The company has added new members to its Board of Directors and management team, implemented new financial controls, and further developed its pipeline of promising drugs for patients with rare diseases while steadily improving its operating performance.
Retrophin, Inc. Chris Cline, CFA Director, Investor Relations 646-564-3680 IR@retrophin.com
News Provided by Acquire Media